8-K: OrthoPediatrics Q1 2026 Revenue Growth and Guidance Hike

OrthoPediatrics reported 13% year-over-year revenue growth to $59.4 million and raised its full-year 2026 revenue guidance.

Summary

• Total revenue reached $59.4 million, a 13% increase from $52.4 million in Q1 2025.
• Domestic revenue grew 11% to $45.3 million, while international revenue surged 22% to $14.1 million.
• Trauma & Deformity revenue rose 14% to $43.0 million; Scoliosis revenue grew 13% to $15.4 million.
• Adjusted EBITDA improved to $2.2 million, compared to a loss of $0.4 million in the prior-year period.
• Free cash flow usage was reduced by 40% year-over-year to $5.0 million.
• Full-year 2026 revenue guidance increased to a range of $263.0 million to $267.0 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, as the company successfully grew revenue while simultaneously improving profitability metrics and raising forward guidance.

Positives

• Double-digit revenue growth across both domestic (11%) and international (22%) segments.
• Significant turnaround in Adjusted EBITDA, moving from a loss of $0.4 million to a positive $2.2 million.
• Improved operational efficiency reflected in a 40% reduction in free cash flow usage.
• Upward revision of full-year 2026 revenue guidance.
• Strong performance in core product categories, specifically Trauma, Deformity, and Scoliosis.

Negatives

• Net loss remained flat at $10.7 million compared to the same period in 2025.
• Total operating expenses increased by 5% to $51.7 million, driven by higher personnel costs and stock-based compensation.
• Cash and cash equivalents decreased to $12.2 million from $19.6 million at year-end 2025.
• Other expenses rose to $2.5 million, largely due to a decrease in foreign exchange gains.

Risks

• Ongoing reliance on international markets which are subject to foreign exchange volatility.
• Potential impact of health emergencies or infectious disease outbreaks on product demand.
• Integration risks associated with small-scale acquisitions and clinic expansions.
• Continued net losses and the need to maintain sufficient liquidity for operations.
• Sensitivity to regulatory changes, including EU Medical Device Regulation fees.

Future Outlook

The company raised its full-year 2026 revenue guidance to $263.0 million $267.0 million. It expects annual set deployment of approximately $10.0 million, $25.0 million in adjusted EBITDA, and breakeven free cash flow for the full year.

Management Comments

• We delivered a strong start to 2026 with 13% first quarter revenue growth and significant improvement in adjusted EBITDA and free cash flow.
• We are entering a highly compelling phase, underpinned by a multi-year product super cycle expected to drive higher ASPs, margin expansion, and improved returns.

Industry Context

StockSavvy.ai notes that OrthoPediatrics continues to solidify its niche dominance in the pediatric-specific orthopedic market. The shift toward positive Adjusted EBITDA despite ongoing net losses suggests a successful transition toward operational scale, aligning with broader med-tech trends of prioritizing profitability over pure top-line growth.

Comparison to Industry Standards

• Revenue growth of 13% outperforms many mature orthopedic peers, reflecting the company's specialized focus.
• Gross margin of 73% is competitive with high-end orthopedic device manufacturers.
• The company's focus on pediatric-specific sets provides a defensive moat compared to generalist orthopedic competitors like Stryker or Zimmer Biomet.

Stakeholder Impact

• Shareholders: Positive outlook due to guidance hike and improved EBITDA.
• Employees: Continued growth supports ongoing personnel requirements.
• Customers: Expansion of product offerings and clinic partnerships.

Next Steps

• Execution of the multi-year product super cycle.
• Continued scaling of the OPSB business.
• Monitoring of breakeven free cash flow targets for full-year 2026.

Key Dates

Recommendation

The combination of double-digit revenue growth, a pivot to positive adjusted EBITDA, and an increase in full-year guidance indicates strong operational momentum, making it an attractive prospect for growth-oriented investors.

Keywords

OrthoPediatrics, pediatric orthopedics, medical devices, KIDS, trauma and deformity, scoliosis, earnings report